Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. clinically enabling safety study
Show results for
Products
Services
Software
Training
Applications

Companies

News
Articles
Books
Magazines
Downloads
Videos

Refine by
Date

  • This month
  • This Year
  • Older

Clinically Enabling Safety Study Articles & Analysis

1,255 news found

Hemostemix’s Expands its Marketing Team Focused on Sales in Florida

Hemostemix’s Expands its Marketing Team Focused on Sales in Florida

Hemostemix Inc. (TSX-V: HEM; OTCQB: HMTXF; FSE: 2VF0), an autologous stem cell company developing and commercializing VesCell™ (ACP-01), announces the appointment of a seasoned commercial team encompassing marketing, sales, e-commerce and patient care communications, in compliance with federal and state regulations. The appointments enable Hemostemix to sell VesCell™ in Florida to ...

ByHemostemix Inc.


Cells: Hemostemix ACP-01 and NCP-01 Provides the Scientific Basis for Improving the Longevity and Signal Uptake of Brain Computer Implants

Cells: Hemostemix ACP-01 and NCP-01 Provides the Scientific Basis for Improving the Longevity and Signal Uptake of Brain Computer Implants

Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company“) is excited to highlight a groundbreaking research article published in Cells on June?29,?2025, by Dr. Fraser C. Henderson Sr. and Ms. Kelly?Tuchman, exploring how a combination of the patient’s own ACP-01 and NCP-01 (autologous blood-derived cell precursors) may support the long-term ...

ByHemostemix Inc.


Cells: Hemostemix ACP-01 and NCP-01 Provides the Scientific Basis for Improving the Longevity and Signal Uptake of Brain Computer Implants

Cells: Hemostemix ACP-01 and NCP-01 Provides the Scientific Basis for Improving the Longevity and Signal Uptake of Brain Computer Implants

Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company“) is excited to highlight a groundbreaking research article published in Cells on June?29,?2025, by Dr. Fraser C. Henderson Sr. and Ms. Kelly?Tuchman, exploring how a combination of the patient’s own ACP-01 and NCP-01 (autologous blood-derived cell precursors) may support the long-term ...

ByHemostemix Inc.


How Ghrelin links fasting and mood: New data in depression Research

How Ghrelin links fasting and mood: New data in depression Research

Ghrelin, widely recognized as the hunger hormone, is now under the spotlight for its role in mental health. Recent studies suggest that this metabolic signal may influence mood, especially in individuals with major depressive disorder (MDD). This connection between ghrelin and emotional states reveals new possibilities for understanding the gut-brain axis. Ghrelin levels rise during fasting ...

ByBertin Technologies


Enhancing Ergonomics for Dentists and Surgeons: Promoting Health, Efficiency, and Career Longevity

Enhancing Ergonomics for Dentists and Surgeons: Promoting Health, Efficiency, and Career Longevity

Summary Dentists and surgeons devote their professional lives to improving patient health, often engaging in complex procedures that require precision, concentration, and prolonged static or awkward positioning. However, inadequate ergonomics can result in chronic pain, musculoskeletal disorders (MSDs), fatigue, and shortened careers, with studies indicating that up to 80% of these professionals ...

BySurgiTel is a Division of General Scientific Corporation (GSC)


Huateng Pharma's mPEG-pALD Receives FDA DMF Filing Approval

Huateng Pharma's mPEG-pALD Receives FDA DMF Filing Approval

Changsha, China – Hunan Huateng Pharmaceutical Co., Ltd. (Huateng Pharma), a global leader in the development and production of high-quality PEG derivatives, is pleased to announce that its mPEG-pALD (20K) has successfully completed its Drug Master File (DMF) filing with the U.S. Food and Drug Administration (FDA), under DMF No. 040600. This achievement highlights Huateng Pharma’s ...

ByHunan Huateng Pharmaceutical Co. Ltd.


CD Bioparticles Announces Enhanced Online Ordering System for Improved Customer Experience

CD Bioparticles Announces Enhanced Online Ordering System for Improved Customer Experience

CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, recently unveiled its significantly enhanced online ordering system. This latest update on the website aims to streamline the ordering process for customers, demonstrating CD Bioparticles' commitment that prioritize customer experience, while also creating greater workflow control, making it more ...

ByCD Bioparticles


Ace Therapeutics Releases Cardiovascular Disease Model Development Services to Power Up Related Preclinical Research

Ace Therapeutics Releases Cardiovascular Disease Model Development Services to Power Up Related Preclinical Research

Ace Therapeutics is proud to announce the launch of its cardiovascular disease model development services, aiming to empower researchers and pharmaceutical companies with advanced tools and models to accelerate the study of cardiovascular diseases and drug discovery. Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality worldwide, underscoring the urgent need for ...

ByAce Therapeutics


SOPHiA GENETICS Announces Expanded Partnership with Tennessee Oncology

SOPHiA GENETICS Announces Expanded Partnership with Tennessee Oncology

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that Tennessee Oncology, one of the United States’ largest community-based cancer care specialists that treats nearly half of Tennessee’s cancer patients across 35 clinics, has expanded its relationship with SOPHiA GENETICS to advance its cancer research. ...

BySOPHiA Genetics


SOPHiA GENETICS and Genomenon Collaborate to Streamline Genetic Research

SOPHiA GENETICS and Genomenon Collaborate to Streamline Genetic Research

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology leader in data-driven medicine, today announced the next step in the partnership between the Company and Genomenon, a leading genomic intelligence company, to support better, data-driven outcomes in the rare disease and oncology fields. The two companies have expanded the integration of Genomenon’s Mastermind® Genomic ...

BySOPHiA Genetics


Liposomes for Food Applications

Liposomes for Food Applications

CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, is thrilled to announce the launch of its new line of liposomes specifically designed for food applications, offering promising delivery systems to enhance the bioavailability, stability, and taste of various food ingredients. In the field of food science, liposomes have attracted much attention ...

ByCD Bioparticles


SOPHiA Genetics Announces It Joins the European Liquid Biopsy Society at ECP 2024

SOPHiA Genetics Announces It Joins the European Liquid Biopsy Society at ECP 2024

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that the company is joining the European Liquid Biopsy Society (ELBS), a prestigious network consisting of partners from academia and industry with the common goal of making liquid biopsy tests part of the routine standard of care. SOPHiA GENETICS offers a ...

BySOPHiA Genetics


SOPHiA Genetics Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024

SOPHiA Genetics Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an update from the Company’s work with biopharma company Boundless Bio. SOPHiA GENETICS first partnered with Boundless Bio in 2022 to develop and deploy Boundless Bio’s extrachromosomal DNA (ecDNA) detection algorithm as a clinical trial device, to ...

BySOPHiA Genetics


CD Bioparticles Simplifies Multi-Analyte Detection with Advanced Multiplex Particles

CD Bioparticles Simplifies Multi-Analyte Detection with Advanced Multiplex Particles

With years of experience in the pharmaceutical and life science sectors, CD Bioparticles announces its advanced line of multiplex fluorescence particles designed to streamline complex biological assays in flow cytometry experiments. These particles exhibit low signal widths in the forward scatter, side scatter and fluorescence channels. Various surface modifications, channels and sizes are also ...

ByCD Bioparticles


CD Bioparticles Announces Advanced Capabilities in Customized Liposomes for Targeted Delivery

CD Bioparticles Announces Advanced Capabilities in Customized Liposomes for Targeted Delivery

CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, is proud to announce its expanded capabilities in Customized Liposomes. This advancement allows researchers and developers to leverage the power of liposome technology for a wider range of applications. Liposomes are small spherical artificial vesicles (typically 50-500 nm in diameter) composed ...

ByCD Bioparticles


Studying Flow-Induced Pulmonary Hypertension and Compensatory Lung Growth: Insights from A Novel Murine Model

Studying Flow-Induced Pulmonary Hypertension and Compensatory Lung Growth: Insights from A Novel Murine Model

In the realm of pulmonary research, the search to understand complex lung conditions has led to the development of various animal models. Among these, a new murine model from Tsijis et al stands out for its potential to investigate flow-induced pulmonary hypertension (PH) and compensatory lung growth (CLG). This blog outlines this innovative model, its significance, and the method of ...

BySCIREQ - an emka TECHNOLOGIES Company


CanaQuest Announces Key Appointments to Team to Drive CQ-001 through Clinical Trials

CanaQuest Announces Key Appointments to Team to Drive CQ-001 through Clinical Trials

CanaQuest Medical Corp (“CanaQuest” or the “Company”) (OTC: CANQF), is pleased to announce strategic additions to its executive team with expertise in conducting clinical trials and US FDA drug approval success. The team plans to effectively navigate the regulatory approval process for Drug Candidate, CQ-001 (cannabidiol + proprietary API composition), to treat rare ...

ByCanaQuest Medical Corp.


Comparison of the Rapid Bactericidal Efficacy of Commercially Available Surgical Solutions

Comparison of the Rapid Bactericidal Efficacy of Commercially Available Surgical Solutions

Introduction Intraoperative irrigation is a commonly used method aimed at reducing microbial burden by removing tissue debris, metabolic waste, and tissue exudate from the surgical field prior to site closure.1 With the absence of universally established standard of care and robust clinical data, the selection of appropriate irrigation solution remains a topic of debate. Isotonic saline has ...

BySanara MedTech Inc.


CD Bioparticles Introduces New Polyolefin Family Polymers for Drug Delivery Applications

CD Bioparticles Introduces New Polyolefin Family Polymers for Drug Delivery Applications

CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has recently expanded its low PDI polymer portfolio and announces its new offering of Polyolefin Family polymers with a wide range of properties that make them well-suited for a variety of drug delivery applications. Low dispersion index polymers are polymeric compounds with low molecular weight ...

ByCD Bioparticles


Biopharma Stock News Bite - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) Spikes on News Potential Treatment for Alcohol Use Disorder

Biopharma Stock News Bite - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) Spikes on News Potential Treatment for Alcohol Use Disorder

Investorideas.com (www.investorideas.com) Biotech Stock News Bites - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders made the NASDAQ Top ten percentage gainers today on news. The stock is trading at $2.0050, up $0.8750, gaining +77.0925% on volume of over 8o ...

ByInvestorideas.com

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT